Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298147 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4ELMNAFOLH1CA12 | |
| SCHEMBL6955548 | 0.87 | FOLH1 (0.46) | FOLH1LTA4HSLC1A1SLC1A3SLC1A2 | |
| SCHEMBL27577506 | 0.87 | L3MBTL1 (0.40) | FOLH1LTA4H | |
| SCHEMBL7741119 | 0.87 | L3MBTL1 (0.40) | FOLH1LTA4H | |
| SCHEMBL7734983 | 0.86 | LTA4H (0.43) | ALDH1A1KDM4ELMNALTA4H | |
| SCHEMBL8910551 | 0.82 | PTGES (0.42) | — | |
| SCHEMBL16166282 | 0.81 | SLC1A3 (0.41) | ALDH1A1LMNATDP1SLC1A1SLC1A3 | |
| SCHEMBL7515528 | 0.81 | SLC1A3 (0.38) | ALDH1A1FOLH1LTA4HSLC1A1SLC1A3 | |
| SCHEMBL10686536 | 0.80 | CYP1A2 (0.43) | FOLH1SLC1A1SLC1A3SLC1A2MEN1 | |
| SCHEMBL11051963 | 0.79 | MAOB (0.48) | ALDH1A1KDM4ELMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924307-B2 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | TAKAHASHI KANJI (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6569899-B1 | Such as 5-ethoxymethoxy-4(S)-(N-(4-iodophenylcarbonyl)amino) pentanoic acid methyl ester for inhibiting matrix metalloproteinase; for treatment of rheumatoid diseases, arthrosteitis, osteoarthritis, and osteoporosis | ONO PHARMACEUTICALS CO., LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| EP-1167346-A1 | 4-AMINOBUTANOIC ACID DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002480-A1 | Aminobutyric acid derivatives and pharmaceutical composition containing the same as active ingredient | GABBR1, GABRB1, GABBR2 | ALDH1A1 348/4885KDM4E 3445/4885LMNA 4149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.